| Bioactivity | Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer[1][2][3][4][5]. |
| Invitro | Sintilimab (150 ng/μL, 12 小时) 在人外周血单核细胞 (PBMCs) 中显示出高水平的 PD-1 结合能力和优越的 T 细胞激活特性[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Sintilimab (Anti-PD-1) 相关抗体: |
| In Vivo | Sintilimab (0.1 mg/kg, 1 mg/kg 和 10 mg/kg，腹腔注射, 单次剂量, 1, 8, 12, 5 天) 在人源化小鼠模型中显示出对 NCI-H292 肿瘤的抗肿瘤作用[2]。Sintilimab (1 mg/kg, 3 mg/kg 和 10 mg/kg, 皮下注射, 单剂量) 在 NCI-H292 肿瘤携带的 NOG 小鼠中对 PD-1 分子表现出很高的亲和力[2]。Sintilimab (20 mg/kg, 腹腔注射, 2 天一次，连续 21 天) 联合益生元抑制肺腺癌移植瘤体积，减轻肝、肾损伤[4]。Sintilimab (10 mg/kg, 静脉注射，单剂量) 在 hPD-1 敲入小鼠中的药代动力学参数[2]Parameter |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sheridan M Hoy. Sintilimab: First Global Approval Drugs. 2019 Feb;79(3):341-346. [2]. Wang J, et al Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs. 2019 Nov-Dec;11(8):1443-1451. [3]. Zhang L, et al. Sintilimab: A Promising Anti-Tumor PD-1 Antibody. Front Oncol. 2020 Nov 26;10:594558. [4]. Yan Q, et al. Prebiotics Modulate Gut Microbiota-mediated T-cell Immunity to Enhance the Inhibitory Effect of Sintilimab in Lewis Lung Adenocarcinoma Model Mice. Anticancer Agents Med Chem. 2023;23(17):1966-1973. [5]. Zhang L, et al. Sintilimab for the treatment of non-small cell lung cancer. Biomark Res. 2022 Apr 18;10(1):23. |